Online citations, reference lists, and bibliographies.
← Back to Search

Evaluating Bleeding Severity In Immune Thrombocytopenia (ITP)

C. Neunert
Published 2010 · Medicine

Save to my Library
Download PDF
Analyze on Scholarcy Visualize in Litmaps
Share
Reduce the time it takes to create your bibliography by a factor of 10 by using the world’s favourite reference manager
Time to take this seriously.
Get Citationsy
Despite immune thrombocytopenia (ITP) being one of the most common conditions encountered by the pediatric hematologist, relatively few prospective investigations of ITP exist, and treatment approaches remain highly variable. The ideal prospective clinical trial would use a reduction in severe bleeding as an outcome; however, recent data shows that due to the rarity of severe bleeding events such a trial is not feasible due to the large number of children needed to be enrolled on such studies. Therefore, platelet count is often used a surrogate risk for bleeding severity and an increase in platelet count as the primary outcome in clinical trials. Reliance solely on the platelet count fails to account for relevant patient-related outcomes, among them bleeding severity. Bleeding assessment instruments published to date lack validity and reliability. Therefore, rigorous methods to design and analysis of patient-related outcome measurement tools need to be applied. Once designed appropriately, these measures can be applied to enhance research and help to guide treatment for those patients who truly need it.
This paper references
10.1136/adc.67.8.1056
Guidelines for management of idiopathic thrombocytopenic purpura. The British Paediatric Haematology Group.
O. Eden (1992)
10.1182/BLOOD.V88.1.3.BLOODJOURNAL8813
Idiopathic thrombocytopenic purpura: a practice guideline developed by explicit methods for the American Society of Hematology.
J. George (1996)
Idiopathic thrombocytopenic purpura: a practice guideline developed by explicit methods for the
J N George (1996)
10.1016/S0140-6736(97)04143-3
Assessment of UK practice for management of acute childhood idiopathic thrombocytopenic purpura against published guidelines
P. Bolton-Maggs (1997)
10.1111/j.1365-2141.1999.01409.x
Management of childhood idiopathic thrombocytopenic purpura
J. Lilleyman (1999)
10.3324/%X
Acute childhood idiopathic thrombocytopenic purpura: AIEOP consensus guidelines for diagnosis and treatment. Associazione Italiana di Ematologia e Oncologia Pediatrica.
D. De Mattia (2000)
10.1067/MPD.2002.128547
Grading of hemorrhage in children with idiopathic thrombocytopenic purpura.
G. Buchanan (2002)
10.1097/00043426-200301000-00011
Development of Disease-Specific Health-Related Quality-of-Life Instruments for Children With Immune Thrombocytopenic Purpura and Their Parents
D. Barnard (2003)
10.1182/BLOOD.V104.11.3030.3030
Quantitative Assessment of Drug Treatment Side Effects in Children with Idiopathic Thrombocytopenic Purpura (ITP).
G. Buchanan (2004)
Quantitative assessment of drug treatment side Ann Hematol (2010) 89 (Suppl 1):S47–S50 S49 effects in children with idiopathic thrombocytopenic purpura (ITP)
GR Buchanan (2004)
Disseminated intravascular coagulation associated with acute hemoglobinemia or hemoglobinuria following Rh(0)(D) immune globulin intravenous administration for immune thrombocytopenic purpura.
A. Gaines (2005)
10.1182/BLOOD-2004-11-4303
Disseminated intravascular coagulation associated with acute hemoglobinemia or hemoglobinuria following Rho(D) immune globulin intravenous administration for immune thrombocytopenic purpura
A. Gaines (2005)
10.1002/pbc.20977
Development of a disease‐specific quality of life questionnaire for children & adolescents with idiopathic thrombocytopenic purpura (ITP‐QoL)
S. von Mackensen (2006)
10.1016/S0084-3954(08)70033-2
Prospective Phase 1/2 Study of Rituximab in Childhood and Adolescent Chronic Immune Thrombocytopenic Purpura
J. Stockman (2007)
10.1016/J.JPEDS.2007.01.037
Validity, reliability, and responsiveness of a new measure of health-related quality of life in children with immune thrombocytopenic purpura: the Kids' ITP Tools.
R. Klaassen (2007)
10.1111/j.1365-2141.2007.06635.x
The immune thrombocytopenic purpura (ITP) bleeding score: assessment of bleeding in patients with ITP
Lemke K. Page (2007)
10.1186/1477-7525-5-11
A disease-specific measure of health-related quality of life for use in adults with immune thrombocytopenic purpura: Its development and validation
S. Mathias (2007)
10.1002/pbc.20830
A cost‐utility analysis of treatment for acute childhood idiopathic thrombocytopenic purpura (ITP)
Sarah H. O'Brien (2007)
Validity, reliability, and responsiveness of a new measure of health-related quality of life in children with immune thrombocytopenic purpura: the Kids
RJ Klaassen (2007)
10.1186/1477-7525-6-13
Impact of chronic Immune Thrombocytopenic Purpura (ITP) on health-related quality of life: a conceptual model starting with the patient perspective
S. Mathias (2008)
10.1182/blood-2008-03-138487
Severe hemorrhage in children with newly diagnosed immune thrombocytopenic purpura.
C. Neunert (2008)
10.1007/978-1-59745-385-1_9
Measurement and analysis of patient-reported outcomes.
K. Meyer (2009)
10.1185/03007990802634119
Evaluating clinically meaningful change on the ITP-PAQ: preliminary estimates of minimal important differences
S. Mathias (2009)
10.1185/03007990802634119
Evaluating clinically meaningful change on the ITP-PAQ: preliminary estimates of minimal important differences.
S. Mathias (2009)
10.1007/978-1-59745-385-1_12
Qualitative research in clinical epidemiology.
D. Gregory (2009)
10.1182/blood-2008-07-162503
Standardization of terminology, definitions and outcome criteria in immune thrombocytopenic purpura of adults and children: report from an international working group.
F. Rodeghiero (2009)



This paper is referenced by
Semantic Scholar Logo Some data provided by SemanticScholar